Draft Guidance on Aspirin

Active Ingredient:  
Aspirin

Dosage Form: Route:  
Extended release capsule; oral

Recommended Studies:  
Two studies

1. Type of study: Fasting  
   Design: Single-dose, two-way crossover in vivo  
   Strength: 162.5 mg  
   Subjects: Healthy males and non-pregnant, non-lactating females, general population  
   Additional comments: None.

2. Type of study: Fed  
   Design: Single-dose, two-way crossover in vivo  
   Strength: 162.5 mg  
   Subjects: Healthy males and non-pregnant, non-lactating females, general population  
   Additional comments: None.

Analytes to measure (in appropriate biological fluid):  
Acetylsalicylic acid and its active metabolite, salicylic acid in plasma  
Submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and C\text{max}.

Bioequivalence based on (90% CI):  
Acetylsalicylic acid

Waiver request of in vivo testing:  
Not applicable.

Dissolution test method and sampling times:  
The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location:  
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).
In addition to the method above, for modified release products, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer) should be submitted in the application. Agitation speeds may have to be increased if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Please include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.

Due to a concern of dose dumping of drug from this drug product when taken with alcohol, the Agency currently requests that additional dissolution testing be conducted using various concentrations of ethanol in the dissolution medium, as follows:

Testing Conditions: Volume: 900 mL 0.01N HCl, apparatus 2 (Paddle)@100 rpm, with and without the alcohol;

Test 1: Twelve units tested according to the proposed method, with data collected every 15 minutes for a total of 2 hours

Test 2: Twelve units analyzed by substituting 5% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Test 3: Twelve units analyzed by substituting 20% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Test 4: Twelve units analyzed by substituting 40% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Both test and RLD products must be tested accordingly and data must be provided on individual unit, means, range and %CV on all strengths.